Ceniceros Ashley G, Shridhar Nupur, Fazzari Melissa, Felsen Uriel, Fox Aaron D
Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Albert Einstein College of Medicine, Bronx, New York, USA.
Open Forum Infect Dis. 2021 Feb 18;8(3):ofab083. doi: 10.1093/ofid/ofab083. eCollection 2021 Mar.
The opioid crisis in the United States has led to increasing hospitalizations for drug use-associated infective endocarditis (DUA-IE). Outpatient parenteral antimicrobial therapy (OPAT), the preferred modality for intravenous antibiotics for infective endocarditis, has demonstrated similar outcomes among patients with DUA-IE versus non-DUA-IE, but current studies suffer selection bias. The utilization of OPAT for DUA-IE more generally is not well studied.
This retrospective cohort study compared OPAT use for DUA-IE versus non-DUA-IE in adults hospitalized between January 1, 2015 and September 1, 2019 at 3 urban hospitals. We used multivariable regression analysis to assess the association between DUA-IE and discharge with OPAT, adjusting for clinically significant covariables.
The cohort included 518 patients (126 DUA-IE, 392 non-DUA-IE). Compared to those with non-DUA-IE, DUA-IE patients were younger (53.0 vs 68.2 years, < .001) and more commonly undomiciled (9.5% vs 0.3%, < .01). Patients with DUA-IE had a significantly lower odds of discharge with OPAT than non-DUA-IE patients (adjusted odds ratio [aOR] = 0.20; 95% confidence interval [CI], 0.10-0.39). Odds of discharge with OPAT remained lower for patients with DUA-IE after excluding undomiciled patients (aOR = 0.22; 95% CI, 0.11-0.43) and those with patient-directed discharges (aOR = 0.27; 95% CI, 0.14-0.52).
Significantly fewer patients with DUA-IE were discharged with OPAT compared to those with non-DUA-IE, and undomiciled patients or patient-directed discharges did not fully account for this difference. Efforts to increase OPAT utilization among patients with DUA-IE could have important benefits for patients and the healthcare system.
美国的阿片类药物危机导致与药物使用相关的感染性心内膜炎(DUA-IE)住院人数不断增加。门诊胃肠外抗菌治疗(OPAT)是治疗感染性心内膜炎静脉用抗生素的首选方式,在DUA-IE患者与非DUA-IE患者中已显示出相似的治疗效果,但目前的研究存在选择偏倚。对于DUA-IE更广泛地使用OPAT的情况尚未得到充分研究。
这项回顾性队列研究比较了2015年1月1日至2019年9月1日期间在3家城市医院住院的成年患者中,DUA-IE患者与非DUA-IE患者使用OPAT的情况。我们使用多变量回归分析来评估DUA-IE与OPAT出院之间的关联,并对具有临床意义的协变量进行调整。
该队列包括518名患者(126名DUA-IE患者,392名非DUA-IE患者)。与非DUA-IE患者相比,DUA-IE患者更年轻(53.0岁对68.2岁,<0.001),且无固定住所的情况更常见(9.5%对0.3%,<0.01)。与非DUA-IE患者相比,DUA-IE患者出院时接受OPAT的几率显著更低(调整后的优势比[aOR]=0.20;95%置信区间[CI],0.10-0.39)。在排除无固定住所的患者(aOR=0.22;95%CI,0.11-0.43)和自行要求出院的患者后(aOR=0.27;95%CI,0.14-0.52),DUA-IE患者出院时接受OPAT的几率仍然较低。
与非DUA-IE患者相比,接受OPAT出院的DUA-IE患者明显更少,且无固定住所患者或自行要求出院并不能完全解释这种差异。提高DUA-IE患者中OPAT利用率的努力可能对患者和医疗系统具有重要益处。